- Zacks Small Cap Research•5 days ago
Cryoport (CYRX) reported financial results for their fiscal 2017 third quarter ending December 31st. (Note that the company is transitioning their fiscal year to that of the calendar year – our model beginning with this report reflects the new calendar-year reporting. CYRX has filed a 10-KT Transition Report and will begin reporting under the calendar year format beginning with the period ending March 31, which will now represent their first quarter). Q3 revenue, at $2.2M, was up 53% yoy and about 5% higher than our estimate. It is also a new record and up almost 13% sequentially from fiscal Q2 ’17. Results in the period ending December 31st shows that revenue has come in slightly better than our estimates for the third straight quarter with operating loss much better than our numbers for the second period in a row. While the specific reasons behind the revenue beat is tough to pinpoint, better than anticipated performance of the animal health and reproductive medicine segments has been a contributor.
- Motley Fool•8 days ago
The potential to commercialize an entirely new approach to battling cancer is sparking a big rally in this biotech upstart.
- Business Wire•9 days ago
Kite Announces Appointment of Renowned Cancer Researcher, Owen N. Witte, M.D., to its Board of Directors
Kite Pharma, Inc. today announced that Owen N. Witte, M.D., the founding director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California Los Angeles and a renowned cancer researcher, has been appointed to its Board of Directors.
KITE : Summary for Kite Pharma, Inc. - Yahoo Finance
Kite Pharma, Inc. (KITE)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||74.10 x 100|
|Ask||78.00 x 100|
|Day's Range||74.58 - 77.75|
|52 Week Range||39.82 - 88.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-14.08|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|